{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T11:11:23Z","timestamp":1717153883800},"reference-count":54,"publisher":"American Society of Consultant Pharmacists","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Consultant Pharmacist"],"published-print":{"date-parts":[[2007,3,1]]},"DOI":"10.4140\/tcp.n.2007.239","type":"journal-article","created":{"date-parts":[[2011,1,13]],"date-time":"2011-01-13T02:13:13Z","timestamp":1294884793000},"page":"239-248","source":"Crossref","is-referenced-by-count":10,"title":["Diagnosis and Treatment of Myasthenia Gravis"],"prefix":"10.4140","volume":"22","author":[{"given":"Stephanie E.","family":"Matney","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danny R.","family":"Huff","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2625","published-online":{"date-parts":[[2009,7,2]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1212\/WNL.55.1.16","article-title":"Myasthenia gravis. Recommendations for clinical research standards","volume":"55","author":"A Jaretzki","year":"2000","journal-title":"Neurology"},{"key":"2","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1056\/NEJM199406233302507","article-title":"Myasthenia gravis","volume":"330","author":"D Drachman","year":"1994","journal-title":"N Engl J Med"},{"key":"3","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1016\/S0140-6736(00)05186-2","article-title":"Myasthenia gravis","volume":"357","author":"A Vincent","year":"2001","journal-title":"Lancet"},{"key":"4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1055\/s-2004-829584","article-title":"A history of treatments for myasthenia gravis","volume":"24","author":"J Keesey","year":"2004","journal-title":"Semin Neurol"},{"key":"5","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/j.1749-6632.1981.tb33764.x","article-title":"The natural course of myasthenia gravis and effect of therapeutic measures","volume":"377","author":"D Grob","year":"1981","journal-title":"Ann N Y Acad Sci"},{"key":"6","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1196\/annals.1254.053","article-title":"The epidemiology of myasthenia gravis","volume":"998","author":"L Phillips","year":"2003","journal-title":"Ann NY Acad Sci"},{"key":"7","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1001\/jama.293.15.1906","article-title":"Does this patient have myasthenia gravis?","volume":"293","author":"K Scherer","year":"2005","journal-title":"JAMA"},{"key":"8","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/mus.20030","article-title":"Clinical evaluation and management of myasthenia gravis","volume":"29","author":"J Keesey","year":"2004","journal-title":"Muscle Nerve"},{"key":"9","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0002-9343(98)00374-X","article-title":"Disorders of neuromuscular junction ion channels","volume":"106","author":"K Booynyapisit","year":"1999","journal-title":"Am J Med"},{"key":"10","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/archinte.157.4.399","article-title":"Drugs and myasthenia gravis: an update","volume":"157","author":"E Wittbrodt","year":"1997","journal-title":"Arch Intern Med"},{"key":"11","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1055\/s-2004-829595","article-title":"Myasthenia gravis: management of myasthenic crisis and perioperative care","volume":"24","author":"V Jeul","year":"2004","journal-title":"Semin Neurol"},{"key":"12","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.coph.2005.01.010","article-title":"Myasthenia gravis: emerging new therapy options","volume":"5","author":"J Sieb","year":"2005","journal-title":"Curr Opin Pharmacol"},{"key":"13","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1001\/archopht.1976.03910040003001","article-title":"Rapid eye movements in myasthenia gravis, I: clinical observations","volume":"94","author":"D Cogan","year":"1976","journal-title":"Arch Ophthalmol"},{"key":"14","first-page":"262","article-title":"Management of myasthenia gravis","volume":"12","author":"R Schwendimann","year":"2005","journal-title":"Am J Ther"},{"key":"15","first-page":"1002","article-title":"The edrophonium test","volume":"62","author":"R Pascuzzi","year":"2003","journal-title":"Semin Neurol"},{"key":"16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/mus.880130302","article-title":"Edrophonium responsiveness not necessarily diagnostic of myasthenia gravis","volume":"12","author":"S Oh","year":"1990","journal-title":"Muscle Nerve"},{"key":"17","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1055\/s-2004-829594","article-title":"Myasthenia gravis: diagnosis","volume":"24","author":"M Meriggioli","year":"2004","journal-title":"Semin Neurol"},{"key":"18","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1749-6632.1987.tb51321.x","article-title":"Clinical correlations of antibodies that bind, block, or modulate human acetylcholine receptors in myasthenia gravis","volume":"505","author":"F Howard","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"19","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1212\/WNL.26.11.1054","article-title":"Antibody to acetylcholine receptor in myasthenia gravis: prevalence, clinical correlates, and diagnostic value","volume":"26","author":"J Lindstrom","year":"1976","journal-title":"Neurology"},{"key":"20","doi-asserted-by":"crossref","DOI":"10.1002\/ana.410370707","article-title":"Myasthenia gravis: immunological mechanisms and immunotherapy","volume":"37","author":"R Lewis","year":"1995","journal-title":"Ann Neurol"},{"key":"21","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.48.Suppl_5.23S","article-title":"Serologic profile of myasthenia gravis and distinction from the Lambert-Eaton myasthenic syndrome","volume":"48","author":"V Lennon","year":"1997","journal-title":"Neurology"},{"key":"22","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1749-6632.1976.tb47697.x","article-title":"Antibodies to acetylcholine receptors in rabbits: immunochemical and electrophysiological studies","volume":"274","author":"A Penn","year":"1976","journal-title":"Ann NY Acad Sci"},{"key":"23","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1126\/science.180.4088.871","article-title":"Autoimmune response to acetylcholine receptor","volume":"180","author":"J Patrick","year":"1973","journal-title":"Science"},{"key":"24","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1474-4422(03)00306-5","article-title":"Seronegative generalized myasthenia gravis: clinical features, antibodies, and their targets","volume":"2","author":"A Vincent","year":"2003","journal-title":"Lancet Neurol"},{"key":"25","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/mus.880120802","article-title":"Electrodiagnostic approach to defects of neuromuscular transmission","volume":"12","author":"J Keesey","year":"1989","journal-title":"Muscle Nerve"},{"key":"26","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/mus.880150616","article-title":"Diagnostic sensitivity of the laboratory tests in myasthenia gravis","volume":"15","author":"S Oh","year":"1992","journal-title":"Muscle Nerve"},{"key":"27","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1212\/WNL.39.9.1150","article-title":"Ocular pseudomyasthenia or ocular myasthenia \u2018plus\u2019; a warning to clinicians","volume":"39","author":"G Moorthy","year":"1989","journal-title":"Neurology"},{"key":"28","first-page":"377","article-title":"Myasthenia gravis","volume":"104","author":"M Kothari","year":"2004","journal-title":"JAOA"},{"key":"29","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1749-6632.1998.tb10961.x","article-title":"Drug-induced autoimmune myasthenia gravis","volume":"841","author":"A Penn","year":"1998","journal-title":"Ann NY Acad Sci"},{"key":"30","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0733-8619(05)70335-2","article-title":"Acquired myasthenia gravis","volume":"15","author":"J Massey","year":"1997","journal-title":"Neurol Clin"},{"key":"31","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1212\/01.WNL.0000098887.24618.A0","article-title":"Treatment of autoimmune myasthenic gravis","volume":"61","author":"D Richman","year":"2003","journal-title":"Neurology"},{"key":"32","volume-title":"Lexi-Comp drug information handbook","author":"C Lacy","year":"2005"},{"key":"33","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.WNL.0000094122.88929.0B","article-title":"Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability","volume":"61","author":"M Meriggioli","year":"2003","journal-title":"Neurology"},{"key":"34","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1749-6632.1987.tb51325.x","article-title":"Long-term corticosteroid treatment of myasthenia gravis","volume":"505","author":"T Johns","year":"1987","journal-title":"Ann NY Acad Sci"},{"key":"35","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1001\/archneur.57.5.750","article-title":"Treatment of ocular myasthenia with corticosteroids: yes","volume":"57","author":"M Agius","year":"2000","journal-title":"Arch Neurol"},{"key":"36","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1600-0404.2005.00378.x","article-title":"Cyclosporine in the treatment of myasthenia gravis","volume":"111","author":"D Lavrnic","year":"2005","journal-title":"Ann Neurol Scand"},{"key":"37","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.10400","article-title":"Treatment of refractory myasthenia: \u201crebooting\u201d; with high-dose cyclophosphamide","volume":"53","author":"D Drachman","year":"2003","journal-title":"Ann Neurol"},{"key":"38","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mus.10133","article-title":"Use of intravenous pulsed cyclophosphamide in severe, generalized myasthenia gravis","volume":"26","author":"L Gustavo De Feo","year":"2002","journal-title":"Muscle Nerve"},{"key":"39","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1196\/annals.1254.064","article-title":"Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study","volume":"998","author":"M Meriggioli","year":"2003","journal-title":"Ann NY Acad Sci"},{"key":"40","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1212\/01.WNL.0000160392.32894.6D","article-title":"Long-term results of tacrolimus in cyclosporine- and prednisone-dependent myasthenia gravis","volume":"64","author":"J Ponseti","year":"2005","journal-title":"Neurology"},{"key":"41","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/S0303-8467(03)00046-5","article-title":"Tacrolimus hydrate (FK506): therapeutic effects and selection of responders in the treatment of myasthenia gravis","volume":"106","author":"N Wakata","year":"2003","journal-title":"Clin Neurol Neurosurg"},{"key":"42","first-page":"31","article-title":"Anesthetic implications of myasthenia gravis","volume":"69","author":"M Abel","year":"2002","journal-title":"Mount Sinai J Med"},{"key":"43","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1002\/(SICI)1097-4598(199911)22:11<1479::AID-MUS3>3.0.CO;2-B","article-title":"Intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: present status and practical therapeutic guidelines","volume":"22","author":"M Dalakas","year":"1999","journal-title":"Muscles Nerve"},{"key":"44","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"for the Myasthenia Gravis Clinical Study Group. Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis","volume":"41","author":"P Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"45","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1001\/archneur.1982.00510180028007","article-title":"Complications of plasma exchange in neurological patients","volume":"39","author":"R Rodnitzky","year":"1982","journal-title":"Arch Neurol"},{"key":"46","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1046\/j.1525-1594.2001.06717.x","article-title":"Immunoglobulin treatment versus plasma exchange in patients with chronic moderate to severe myasthenia gravis","volume":"25","author":"J Ronsager","year":"2001","journal-title":"Artificial Organs"},{"key":"47","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1001\/archneur.62.11.1689","article-title":"Treatment of myasthenia gravis exacerbation with intravenous immunoglobulin","volume":"62","author":"P Gajdos","year":"2005","journal-title":"Arch Neurol"},{"key":"48","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.48.Suppl_5.64S","article-title":"Experience with IVIG in the treatment of patients with myasthenia gravis","volume":"48","author":"M Dalakas","year":"1997","journal-title":"Neurology"},{"key":"49","first-page":"440","article-title":"Intravenous immunoglobulin in neurological disease: a specialist review","volume":"72","author":"C Wiles","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"50","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1749-6632.1966.tb45497.x","article-title":"The pathology of the thymus gland in myasthenia gravis","volume":"135","author":"B Castleman","year":"1966","journal-title":"Ann NY Acad Sci"},{"key":"51","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1212\/01.WNL.0000032502.89361.0C","article-title":"Thymoma in patient with MG: characteristics and long-term outcome","volume":"59","author":"A Evoli","year":"2002","journal-title":"Neurology"},{"key":"52","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1749-6632.1987.tb51329.x","article-title":"General discussion on therapy in myasthenia gravis","volume":"505","author":"L Rowland","year":"1987","journal-title":"Ann NY Acad Sci"},{"key":"53","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1097\/00000658-197610000-00008","article-title":"The value of thymectomy in myasthenia gravis: a computer-assisted matched study","volume":"184","author":"J Buckingham","year":"1976","journal-title":"Ann Surg"},{"key":"54","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1600-0404.1992.tb05094.x","article-title":"Remission rate after thymectomy in myasthenia gravis when the bias of immunosuppressive therapy is eliminated","volume":"86","author":"C Lindberg","year":"1992","journal-title":"Acta Neurol Scand"}],"container-title":["The Consultant Pharmacist"],"original-title":[],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T20:05:54Z","timestamp":1559937954000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ingentaconnect.com\/content\/ascp\/tcp\/2007\/00000022\/00000003\/art00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,1]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,3,1]]}},"alternative-id":["XJ2L757Q43601X15"],"URL":"https:\/\/doi.org\/10.4140\/tcp.n.2007.239","relation":{},"ISSN":["0888-5109"],"issn-type":[{"value":"0888-5109","type":"print"}],"subject":[],"published":{"date-parts":[[2007,3,1]]}}}